Wednesday, December 17, 2008

VLST Gets Investment, In Deal With Novo Nordisk

Seattle-based VLST, which is developing biopharmaceuticals focused on treating autoimmune and inflammatory disorders, has scored $12M in an investment from pharmaceuticals firm Novo Nordisk A/S, as part of a collaboration deal. According to Novo Nordisk, it is providing VLST with upfront payment for rights to VLST's technology, in addition to milestone payments.